Detail

1ST HALF-YEAR 2011: Sales up 10%, solid performance in a disrupted environment and upward revision of full-year targets

 

 Antony, France; 13 July 2011 – 6pm

 

HY1 sales
Consolidated sales for the first half of 2011 were € 121.7 million, compared to € 110.6 million during the same period of the previous financial year. The European market experienced a moderate but genuine decline, owing to the strong economic recession in Southern Europe and the regulatory discount in Germany. The weak 2010 pollen season also had a negative impact, in particular in the second quarter of 2011.

Against this backdrop, with growth of 10% in the first half of the year (8% in the second quarter), Stallergenes’sales development reflected a market share gain that was primarily due to the successful launch of Oralair® in several European countries (not including France).

 

» Voor het VOLLEDIGE PERSBERICHT, klik hier